Background: “A Trigeminal neuralgia is a frequent and painful condition which in mostly Idiopathic and is rated by the patients as worst of all pains that afflict the mankind, affecting the all age group people”. TGN in characterized by paroxystic episodes of lancing, or burning pain or pain felt as electric discharges, that present spontaneously or may be caused by the action of auditory or cutaneous stimuli , the basic pathogenesis is still mysterious. The safe and effective treatment for TGN and chronic pain is a large public health concern. Palmitoylethanolamide (PEA) is
a endogenously produced amide cannabimimetic compound with tissue protection and anti inflammatory activity which is a new class of drug. “Neuropathic pain is defined by international Association for the Study of Pain (IASP), Pain caused by a lesion or disease of the somato sensory nervous system”.

Objectives: The aim and objective of this study is to evaluate the effectiveness and safety of Palmitoylethanolamide (PEA) in the management of patient, suffering from TGN.

Materials and Methods: The Study was conducted in the Neurosurgery unit of Surgery Department in Gandhi Medical College and Associated Hamidia Hospital Bhopal India. A total no. of 40 patients aged 20-78 years were included in the study from Nov 1917 to May 1919 and divided into two groups group I (study group) and the group II (Controlled group) PEA was given to group I to evaluated the effect of PEA in TGN.

Result: We have studied 40 patients with PEA for 60 days and Palmitoylethanolamide 354 mg orally given Three times (TDS) a day for first2 weeks than Two times (bid) a day for 6 week. All patients refused surgery. It is available in India in the Name of Palmiges. PEA was associated with greater pain reduction in Study Group compare to the
controlled group. The primary outcome measure was the mean pain reduction evaluated by VAS scale.

Conclusion: PEA seems to be useful in the treatment of TGN and it is well tolerated in patients with Study Group.
Palmitoylethanolamide (PEA), reduces the inflammation which results in lowering/ reduction of TGN pain and PEA used successfully in the prophylaxis treatment of neuropathic pain. We used PEA in a series of patients surfing from TGN in addition to pharmacological therapy already used. The controlled trials are further needed to prove be efficacy and reliability and also to find out the adverse reaction associated with the drug. Thus, what is needed at this critical juncture is a Solution which corroborates to the care of TGN Pain with No side Effects.

Keywords: PEA; Palmitoylethanolamide; Trigeminal Neuralgia; Analgesics; VAS (Visual Analogue Score); Ticdouloureux.